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ARTICLE
Association Between Prescribed Ibuprofen and Severe 
COVID-19 Infection: A Nationwide Register-Based Cohort 
Study
Kristian Kragholm1,2,*, Thomas A. Gerds3, Emil Fosbøl4, Mikkel Porsborg Andersen5, Matthew Phelps6, Jawad H.  
Butt4, Lauge Østergaard4, Casper N. Bang5,6, Jannik Pallisgaard7, Gunnar Gislason6,7, Morten Schou7, Lars Køber4 and  
Christian Torp-Pedersen5
Recommendations regarding ibuprofen use in relation to coronavirus disease 2019 (COVID-19) have been conflicting. We ex-
amined the risk of severe COVID-19 between ibuprofen-prescribed and non-ibuprofen patients with COVID-19 in a nationwide 
register-based study of patients with COVID-19 in Denmark between the end of February 2020 and May 16, 2020. Patients 
with heart failure (n = 208), < 30 years (n = 575), and prescribed other nonsteroidal anti-inflammatory drugs (n = 57) were 
excluded. Patients with ibuprofen prescription claims between January 1, 2020, and before COVID-19 diagnosis or April 30, 
2020 (last available prescription) were compared with patients without ibuprofen prescription claims. Outcome was a 30-day 
composite of severe COVID-19 diagnosis with acute respiratory syndrome, intensive care unit admission, or death. Absolute 
risks and average risk ratios comparing outcome for ibuprofen vs. non-ibuprofen patients standardized to the age, sex, and 
comorbidity distribution of all patients were derived from multivariable Cox regression. Among 4,002 patients, 264 (6.6%) 
had ibuprofen prescription claims before COVID-19. Age, sex, and comorbidities were comparable between the two study 
groups. Standardized absolute risks of the composite outcome for ibuprofen-prescribed vs. non-ibuprofen patients were 
16.3% (95% confidence interval (CI) 12.1–20.6) vs. 17.0% (95% CI 16.0–18.1), P = 0.74. The standardized average risk ratio for 
ibuprofen-prescribed vs. non-ibuprofen patients was 0.96 (95% CI 0.72–1.23). Standardized absolute risks of the composite 
outcome for patients with ibuprofen prescription claims > 14 days before COVID-19 vs. ≤ 14 days of COVID-19 were 17.1% 
(95% CI 12.3–22.0) vs. 14.3% (95% CI 7.1–23.1). In conclusion, in this nationwide study, there was no significant association 
between ibuprofen prescription claims and severe COVID-19.
The coronavirus disease 2019 (COVID-19) pandemic 
caused by severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) has led to substantial changes in health-
care utilization, morbidity, intensive care resources, and 
mortality.1–7 The entry point for this novel coronavirus for 
its further pathogenesis in humans is thought to be through 
an angiotensin-converting enzyme 2 receptor found in the 
lungs, arteries, heart, kidneys, and intestines.8 Nonsteroidal 
anti-inflammatory drugs (NSAIDs) might facilitate and ag-
gravate infection with COVID-19.9,10 The mechanisms 
may include upregulation of the angiotensin-converting 
enzyme 2 enzyme expression and delayed diagnostics 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Recommendations regarding ibuprofen use in relation 
to coronavirus disease 2019 (COVID-19) have been con-
flicting and to date, no studies have addressed the risk of 
severe COVID-19 between ibuprofen and non-ibuprofen 
users.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  Is ibuprofen prescription redemption associated with 
severe outcome of COVID-19?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  In this nationwide study, there was no significant asso-
ciation between ibuprofen prescription claims and severe 
COVID-19.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔  Ibuprofen prescription to patients with COVID-19 
does not appear to be associated with severe COVID-19 
trajectory.
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by masking inflammation and fever.9,10 Initially, the World 
Health Organization (WHO) and national health boards 
issued a warning against the use of NSAIDs in patients 
with COVID-19 and that paracetamol or acetaminophen 
should be administered instead. However, later and current 
WHO and European Medicine Agency recommendations 
do not call for avoidance of ibuprofen to treat COVID-19 
symptoms, based on the lack of evidence to support the 
initially recommended warning.10 The US Food and Drug 
Administration (FDA) has stated their awareness of reports 
of potential worsening of COVID-19 infection based on 
NSAID use, but the agency also stresses that there is cur-
rently insufficient evidence to support that NSAID should 
worsen the clinical course of COVID-19 infection. Therefore, 
given the current uncertainty about whether NSAID should 
be avoided in patients with COVID-19, we performed a 
nationwide register-based study to evaluate the risk of se-
vere COVID-19 infection with recent ibuprofen prescription 
claims. Because very few patients were prescribed other 
NSAIDs, we only studied the association between ibupro-
fen prescription claims and outcome.
METHODS
Study setting and population
In Denmark, all citizens hold a unique civil registration num-
ber used in all healthcare and social contacts and recorded 
in national administrative registries. From the Danish 
National Patient Registry, we identified patients positive 
with COVID-19 between the end of February 2020 and May 
16, 2020, through the use of International Classification of 
Disease-10th edition diagnosis codes DB342, DB342A, 
and DB972 for unspecific COVID-19 infection and DB972A 
for COVID-19 infection with severe acute respiratory syn-
drome.11 Patients below 30 years of age, as well as patients 
with heart failure, in whom ibuprofen is not recommended, 
were excluded. Finally, only 57 patients were prescribed 
other NSAIDs, and these patients were excluded.
Exposure
From the Danish National Prescription Registry, data on pre-
scription medication was available until April 30, 2020. We 
assessed ibuprofen prescription claims between January 
1, 2020, and April 30, 2020, and the latest filled prescrip-
tion before COVID-19 diagnosis or April 30, 2020, was used. 
Ibuprofen prescription claims were further divided into 
> 14 days before COVID-19 diagnosis vs. ≤ 14 days before 
COVID-19 diagnosis. Finally, because we do not have exact 
data on doses available from the Danish National Prescription 
Registry, we defined strengths of the latest package of 
200–400 mg vs. 600–800 mg, respectively, as low-medium 
vs. high dosage. These 2 groups may be viewed as prox-
ies for daily doses of 600–1,200 mg and 1,800–2,400 mg, 
respectively. Indications for ibuprofen and concomitant pre-
scription for paracetamol were also assessed.
Covariates
We included information on patient age and sex from 
the Danish Civil Registration System. We assessed the 
following comorbidities: hypertension, diabetes, prior myo-
cardial infarction, chronic obstructive pulmonary disease, 
hypertension, any malignancy, and rheumatic disease. 
Hypertension was defined as a redemption of at least 2 anti-
hypertensive drugs in 2 consecutive 100-day periods prior to 
the COVID-19 diagnosis, as done previously.12 All other co-
morbid conditions were identified from the Danish National 
Patient Registry up to 5 years prior to COVID-19 diagnosis.
Outcome
The study outcome was a 30-day composite of severe 
COVID-19 diagnosis (International Classification of Disease-
10th edition: DB972A), admission to an intensive care unit 
(ICU), or death. The Danish National Patient Registry was 
used to identify the first two components of the compos-
ite end point, whereas vital status was identified from the 
Danish Civil Registration System. Patients admitted to an 
ICU 3 days before the COVID-19 diagnosis up to 30 days 
after the COVID-19 diagnosis were defined as admitted to 
an ICU and incorporated into the composite end point. For 
cases where the ICU admission was ahead of the COVID-19 
diagnosis, risk time began at the time of COVID-19 diagnosis.
Statistics
Continuous variables are reported using median and 25–75 
percentiles. Categorical variables are reported using counts 
and percentages. Thirty-day absolute risks and average risk 
ratios (treatment effects) for the ibuprofen vs. non-ibuprofen 
COVID-19 patient groups standardized to the age, sex, and 
comorbidity distribution of all patients were derived from 
multivariable Cox regression.13 The models included the fol-
lowing covariates: age (in groups 30–50, > 50–60, > 60–70, 
> 70–80, and > 80 years), sex, diabetes, prior myocardial 
infarction, chronic obstructive pulmonary disease, hyper-
tension, cancer, and rheumatic disease. Data management 
and analyses were performed using SAS, version 9.4 (Cary, 
NC) and R version 3.6.1.14
Ethics
According to Danish legislation, register-based studies do 
not require ethical committee approval or patient consent. 
In accordance with the General Data Protection Regulation, 
the data responsible institute in the Capital Region of 
Denmark has approved the use of the data sources for re-
search purposes (approval number P-2019-191). Data are 
accessed on secure servers under Statistics Denmark and 
cannot be shared according to Danish legislation.
RESULTS
Patients
Of a total of 4,842 patients with COVID-19 infection between 
the end of February and May 16, 2020, 4,002 patients formed 
the study population. A total of 264 patients (6.6%) filled an 
ibuprofen prescription claim prior to COVID-19 diagnosis. 
Patients with pre-existing heart failure (n = 208), < 30 years 
of age (n = 575), or who filled a prescription for other non-
steroidal anti-inflammatory drugs (n = 57) were excluded.
Characteristics
Characteristics of age, sex, and comorbidities were gener-
ally comparable between the two study groups (Table 1). 
Patients with ibuprofen prescription claims tended to be 
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older and more likely to have hypertension, although insig-
nificant, as well as the prevalence of diabetes, myocardial 
infarction, chronic obstructive pulmonary disease, and 
cancer were numerically higher for patients with ibupro-
fen prescription claims. Characteristics between patients 
with ibuprofen prescription claims >  14  days before 
COVID-19 vs. ≤ 14 days before COVID-19 were also com-
parable (Table 2). Indications for ibuprofen prescription 
were available for 220 patients of 264 patients who were 
prescribed ibuprofen: 13 patients (5.9%) were prescribed 
ibuprofen due to rheumatic disease/inflammation and the 
remaining 207 patients (94.1%) due to pain. Of these 220 
patients, 156 (70.9%) were also prescribed paracetamol.
Absolute risks
A total of 688 patients met the 30-day composite end point, 
42 patients (15.9%) in the ibuprofen group, and 646 patients 
(17.3%) in the non-ibuprofen group (Table 3). Absolute risks 
for the composite end point for patients with vs. without 
an ibuprofen prescription claim standardized to the age, 
sex, and comorbidity distribution of all patients were 16.3% 
(95% CI 12.1–20.6) vs. 17.0% (95% CI 16.0–18.1), P = 0.74. 
Corresponding risks for an ibuprofen prescription claim 
> 14 days before COVID-19 diagnosis vs. ≤ 14 days before 
diagnosis of COVID-19 were 16.0% (95% CI 11.9–20.9) vs. 
14.4% (95% CI 6.7–23.0), P = 0.70 (Table 4).
Average risk ratios
The average risk ratio for patients with vs. without a recent 
ibuprofen prescription claim prior to COVID-19 diagnosis 
standardized to the age, sex, and comorbidity distribution 
of all patients was 0.96 (95% CI 0.72–1.23). The correspond-
ing average risk ratio for ibuprofen prescription claims 
≤  14  days before the COVID-19 diagnosis vs. >  14  days 
before COVID-19 diagnosis (reference) was 0.90 (95% CI 
0.39–1.57).
Table 1 Characteristics of patients with COVID-19 with vs. without an ibuprofen prescription claim prior to COVID-19
Variable
Ibuprofen prescription claim 
(n = 264)
No ibuprofen prescription claim 
(n = 3,738) P value
Age, median [25%–75%] 58 [46–68] 57 [45–73] 0.67
Age ≤ 50 years, n (%) 87 (33.0) 1,359 (36.4)
Age > 50–60 years, n (%) 62 (23.5) 769 (20.6)
Age > 60–70 years, n (%) 56 (21.2) 528 (14.1)
Age > 70–80 years, n (%) 31 (11.7) 575 (15.4)
Age > 80 years, n (%) 28 (10.6) 507 (13.6) 0.007
Male sex, n (%) 118 (44.7) 1,773 (47.4) 0.43
Diabetes, n (%) 35 (13.3) 414 (11.1) 0.32
Prior MI, n (%) 7 (2.7) 94 (2.5) 0.99
COPD, n (%) 17 (6.4) 197 (5.3) 0.50
Hypertension, n (%) 64 (24.2) 815 (21.8) 0.40
Cancer, n (%) 19 (7.2) 362 (9.7) 0.22
Rheumatic disease, n (%) 13 (4.9) 171 (4.6) 0.91
COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; MI, myocardial infarction.
Table 2 Characteristics of patients with COVID-19 with an ibuprofen prescription claim ≤ 14 days before COVID-19 vs. > 14 days before 
COVID-19
Variable
Ibuprofen prescription claim Ibuprofen prescription claim
P value≤ 14 days before COVID-19 (n = 64) > 14 days before COVID-19 (n = 200)
Age, median [25% MI, 75% MI] 58.5 [47.0, 74.2] 57 [46, 68] 0.50
Age ≤ 50 years, n (%) 19 (29.7) 68 (34.0)
Age > 50–60 years, n (%) 16 (25.0) 46 (23.0)
Age > 60–70 years, n (%) 12 (18.8) 44 (22.0)
Age > 70–80 years, n (%) 11 (17.2) 20 (10.0)
Age > 80 years, n (%) 6 (9.4) 22 (11.0) 0.58
Male sex, n (%) 35 (54.7) 83 (41.5) 0.089
Diabetes, n (%) 10 (15.6) 25 (12.5) 0.67
Prior MI, n (%) 4 (6.2) 3 (1.5) 0.11
COPD, n (%) 5 (7.8) 12 (6.0) 0.82
Hypertension, n (%) 18 (28.1) 46 (23.0) 0.51
Cancer, n (%) 6 (9.4) 13 (6.5) 0.62
Rheumatic disease, n (%) NA 11 (5.5) 0.67
COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; MI, myocardial infarction; NA, not available (according to Statistics 
Denmark legislation, cells with number of patients below three cannot be reported).
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Other analyses
The dosage of ibuprofen was not directly available from the 
Danish National Prescription Registry. In analyses applying 
the strength of the ibuprofen, 215 patients were prescribed 
200–400  mg ibuprofen pills and 49 patients were pre-
scribed 600–800  mg ibuprofen pills. The absolute risk of 
the 30-day composite outcome standardized to the age, 
sex, and comorbidity distribution of all patients was 15.2% 
(95% CI 10.7–20.1) for the 200–400  mg ibuprofen group 
vs. 17.2% (95% CI 6.5–27.3) for the 600–800  mg ibupro-
fen group. The average risk ratio standardized to the age, 
sex, and comorbidity distribution of all patients for the 600–
800 mg ibuprofen group vs. 200–400 mg ibuprofen group 
(reference) was 1.13 (95% CI 0.42–1.98).
DISCUSSION
In this nationwide study on the association between ibu-
profen prescription claims and severe COVID-19 infection, 
defined as a COVID-19 diagnosis with severe acute respira-
tory syndrome, ICU admission, or fatal trajectory, we found 
no significant association between recent ibuprofen pre-
scription claims and the composite end point.
Respiratory, septic, and cardiovascular complications 
and prolonged recovery have been linked to NSAID use in 
COVID-19 infectious disease.9,15 In addition to the chang-
ing recommendations regarding ibuprofen and other NSAID 
use in the context of COVID-19 from the WHO and sev-
eral national health boards, several experts have advocated 
against the use of these drugs in patients infected with 
COVID-19 and suggested paracetamol or acetaminophen 
as alternative treatments.15 Currently, the WHO do not call 
for avoidance of ibuprofen to treat COVID-19 symptoms. 
The European Medicine Agency as well as the FDA also 
do not advocate against the use of ibuprofen, and the 
FDA calls for more evidence to support the drug safety of 
NSAIDs, including ibuprofen. Our results do not provide 
sufficient evidence to change the current recommenda-
tions. Reassuringly, the overall results were consistent with 
results in which ibuprofen prescription claims were divided 
into > 14 days before COVID-19 diagnosis vs. ≤ 14 days 
before COVID-19 diagnosis. Finally, although the dosage 
of ibuprofen was not directly available from the Danish 
National Prescription Registry, we used the strength of 
the ibuprofen package of 200–400  mg and 600–800  mg, 
respectively, to divide patients into low-medium vs. high 
dosage groups. In these analyses, we did not find any sig-
nificant differences in severe COVID-19 outcome between 
the two dosage groups.
In our study, ibuprofen users were defined based on 
prescription fills and information on whether or how many 
ibuprofen pills the patients actually took is not available. 
However, the proxies for ibuprofen dosage mentioned 
above did not provide evidence to suggest a dose-re-
sponse relationship between ibuprofen strength and severe 
COVID-19 outcome. In addition, patients on prescription 
ibuprofen are presumably more likely to actually use the 
medication on a more regular and even daily basis. As 
such, the lack of an association with outcome for patients 
who claimed a prescription for ibuprofen within 14 days of 
the COVID-19 diagnosis is likely to be valid. Because ibu-
profen also can be purchased as an over-the-counter drug 
in Denmark, we cannot exclude potential misclassification 
of ibuprofen exposure, as patients in the non-ibuprofen 
group may have used over-the-counter ibuprofen. We did 
not have data on the medication used during hospitaliza-
tion for COVID-19. As such, we do not have information 
on whether ibuprofen use was continued or discontinued, 
which may have had an impact on our results. Whether pa-
tients actually were using ibuprofen or they avoided it on 
Table 3 Absolute risks and average risk ratio of the 30-day composite outcome for patients with COVID-19 with vs. without recent ibuprofen 




Age and sex-adjusted 
absolute risk [95% CI]
Fully adjusted absolute 
risk [95% CI]
Standardized average 
risk ratio [95% CI]
No ibuprofen prescription claim 17.3% [16.1–18.6] 17.0% [15.9–18.0] 17.0% [16.0–18.1] Ref
Ibuprofen prescription claim 16.0% [11.8–20.5] 16.6% [12.7–21.1] 16.3% [12.1–20.6] 0.96 [0.72–1.23]
The 30-day composite outcome consisted of severe COVID-19 diagnosis, intensive care unit admission, or death. The average risk ratio was standardized to 
the age, sex, and comorbidity distribution of all patients.
CI, confidence interval; COVID-19, coronavirus disease 2019; Ref, reference.
Table 4 Absolute risks and average risk ratio of the 30-day composite end point for patients with ibuprofen prescription claims > 14 days vs. 
≤ 14 days before COVID-19 diagnosis
Ibuprofen group
Unadjusted absolute risk 
[95% CI]









Ibuprofen prescription claim 16.0% [10.9–21.2] 16.0% [11.7–20.9] 16.0% [11.9–20.9] Ref
> 14 days before COVID-19
Ibuprofen prescription claim 15.5% [7.0–25.0] 14.6% [7.7–22.6] 14.4% [6.7–23.0] 0.90 [0.39–1.57]
≤ 14 days before COVID-19
The composite outcome consisted of severe COVID-19 diagnosis, intensive care unit admission, or death.
The average risk ratio was standardized to the age, sex, and comorbidity distribution of all patients.
CI, confidence interval; COVID-19, coronavirus disease 2019; Ref, reference.
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the basis of physician advice and/or the public attention 
in March 2020 on the potential negative effect on COVID-
19 infection severity remain unknown. In support of our 
study findings, a limited number of recent studies, includ-
ing reviews, have also not found any evidence suggesting 
worsening of COVID-19 infection in relation to ibuprofen or 
NSAID use.10,16–19 Follow-up data on outcome was limited 
to May 16, 2020, which may limit the registration of severe 
COVID-19 infection for patients diagnosed with COVID-
19 at the end of the study period. However, the majority 
of patients hospitalized for COVID-19 were in the hospital 
in the beginning of April ensuring that the greater majority 
of the included patients had sufficient follow-up to allow 
the study of the 30-day outcome measure. Although we 
adjusted for several confounding factors, we cannot rule 
out residual or unmeasured confounding. Given the obser-
vational design, results, and associations, no conclusions 
concerning causality can be made. However, we applied 
average treatment effect analyses with standardization of 
the age, sex, and comorbidity distribution in an attempt 
to minimize confounding by indication issues and mimic 
a randomized controlled trial setting. For these reasons, 
patients of younger age and with heart failure, in whom 
ibuprofen was not used, were excluded per study design. 
In addition to a lack of laboratory data to confirm that 
each case had a positive swab test, our sample is based 
on hospital registries, including only cases evaluated for 
hospitalization needs and/or hospital-based staff. Although 
most COVID-19 infections in Denmark are located in the 
capital region and more densely populated areas, the use 
of nationwide data minimizes selection bias based on geo-
graphic differences.
CONCLUSIONS
In this nationwide study, we did not find recent ibuprofen 
drug prescription claims prior to COVID-19 diagnosis to be 
significantly associated with severe, including fatal trajec-
tory of COVID-19 infection.
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